# Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder

> **NCT00322595** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 800 (estimated)

## Conditions studied

- Generalized Anxiety Disorder

## Interventions

- **DRUG:** Quetiapine fumarate
- **DRUG:** Paroxetine

## Key facts

- **NCT ID:** NCT00322595
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** —
- **Final completion:** 2007-05
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2008-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00322595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00322595, "Efficacy and Safety Study of Seroquel SR in the Treatment of Generalized Anxiety Disorder". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00322595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*